Indivior Stock Price, News & Analysis

Indivior PLC (NASDAQ/LSE: INDV) has announced its participation in three major investor events in June 2025. CEO Joe Ciaffoni and CFO Ryan Preblick will attend:

1. Jefferies Global Healthcare Conference in New York City on June 4th, featuring 1x1/group meetings and a fireside discussion at 9:55 a.m. ET (publicly available via webcast)

2. Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 11th, hosting 1x1/group meetings

3. Northland Growth Conference 2025, a virtual event on June 25th, conducting 1x1/group meetings

Interested investors need to contact their respective conference representatives to schedule meetings.

Indivior PLC (INDV) announced a groundbreaking study on SUBLOCADE®, their monthly buprenorphine depot injection for treating opioid use disorder (OUD) during pregnancy. The study, published in the American Journal on Addictions, analyzed data from three sources: clinical case studies of four pregnant patients, five-year postmarketing surveillance data covering 322 pregnancy exposures, and a targeted literature review. Key findings showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates. All four patients in the clinical case studies delivered healthy, full-term infants with normal birthweight and no neonatal opioid withdrawal syndrome. This research is particularly significant as opioid use during pregnancy increased 131% between 2010-2017, with pregnancy-related overdose deaths involving fentanyl rising from 5.73 to 9.47 per 100,000 from 2017-2020.

Indivior (Nasdaq/LSE: INDV) has announced the release of its Q1 2025 financial results for the period ending March 31, 2025. The company has made available its earnings release and investor presentation on their corporate website www.indivior.com.

A live webcast presentation is scheduled for 13:00 BST (8:00 am ET), to be hosted by CEO Mark Crossley. Participants can access the presentation through a webcast link or join telephonically by registering through the provided registration link.

Indivior PLC (NASDAQ/LSE: INDV) has announced significant changes to its Board of Directors, following previous appointments and discussions with Oaktree Capital Management. The key changes include:

- Reducing board size to seven directors for the 2025 AGM
- Peter Bains and Jo LeCouilliard will not seek re-election
- Robert Schriesheim stepped down effective March 2, 2025
- Search for one new Independent Non-Executive Director by July 1, 2025
- Daniel Ninivaggi appointed as Chair of Nomination Committee from March 10, 2025
- Barbara Ryan to become Chair of Compensation Committee after AGM
- Discontinuation of Operational Committee

These changes follow recent appointments including Dr. David Wheadon as Chair, Daniel Ninivaggi as Independent Non-Executive Director, and Joe Ciaffoni as CEO. The company has entered an amended Relationship Agreement with Oaktree Capital Management.

Indivior PLC (INDV) has appointed Joe Ciaffoni as its new Chief Executive Officer, effective upon shareholder approval at the May 2025 AGM. Ciaffoni, 53, who joined as an Independent Non-Executive Director in December 2024, brings over 30 years of pharmaceutical and biotech experience, having previously served as President and CEO of Collegium Pharmaceutical.

Current CEO Mark Crossley will step down following his tenure since June 2020, but will remain to support the transition until at least May 2025. Under Crossley's leadership, the company strengthened its commitment to patients and expanded treatment access for substance use disorders.

Ciaffoni's appointment aims to fuel Indivior's next growth phase in addiction treatment, where the company maintains a global portfolio of OUD treatments and employs over 1,000 individuals with products available in more than 30 countries.

Indivior (NASDAQ/LSE: INDV) announced FDA approval of significant label changes for SUBLOCADE®, their treatment for moderate to severe opioid use disorder (OUD). The key updates include a rapid initiation protocol that reduces treatment initiation time from one week to one hour, and new alternative injection sites including abdomen, thigh, buttock, and back of upper arm.

The rapid initiation protocol allows healthcare providers to start SUBLOCADE treatment after a single dose of transmucosal buprenorphine and a one-hour observation period. A non-inferiority study with 729 participants demonstrated the effectiveness of rapid initiation, with 66.4% of patients in the rapid induction arm receiving a second injection compared to 54.5% in the standard induction arm. Of the study participants, 77.5% were fentanyl-positive at induction.

These changes aim to reduce treatment obstacles and improve patient adherence while maintaining SUBLOCADE's established safety profile and efficacy.

Indivior PLC (Nasdaq/LSE: INDV) has announced its financial results for the fiscal year and fourth quarter of 2024, ending December 31, 2024. The company will host a live webcast presentation at 13:00 BST (8:00 am ET), led by CEO Mark Crossley.

The earnings release and investor presentation materials are available on the company's website at www.indivior.com. Participants can join the presentation through a webcast link or register for telephonic access.

Indivior PLC (Nasdaq/LSE: INDV) announced that the FDA has delayed the final review of proposed label changes for SUBLOCADE® (buprenorphine extended-release) Injection. The PDUFA action date was originally scheduled for February 7, 2025. On February 11, 2025, the FDA informed Indivior that while there were no outstanding items to address following acceptance of the proposed label, the final review has been delayed. The proposed changes include rapid initiation protocol and alternative injection sites. The company will provide updates on the approval status as appropriate.

Indivior PLC presented significant findings at CSAM 2024 showing that rapid initiation (RI) with once-monthly SUBLOCADE improves treatment retention for opioid use disorder (OUD) patients compared to standard initiation (SI). The study of 729 participants demonstrated a 12% overall improvement in retention rates, with a 15% increase among fentanyl-positive patients.

The RI protocol involves administering SUBLOCADE within one hour of a single transmucosal buprenorphine dose, followed by a second injection after one week, versus the standard 28-day interval. The FDA has granted Priority Review for label expansion to include rapid initiation and alternative injection sites (thigh, upper arm, and buttocks), with a PDUFA date of February 7, 2025.